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Abstract: Cancers have long been described as the result of successive selections of somatic cells progressively acquiring 
growth and survival advantages. Such a model was hardly compatible with the obvious heterogeneity of the cancer cell 
population present in tumors. This heterogeneity rather suggests that mutations hint multipotent cells that, in addition to the 
resulting proliferation and survival advantages, display differentiation capabilities. Adult stem cells or progenitors display 
similar properties, supporting the concept that cancers actually originate from these cells. The recent observation that 
differentiated cells can dedifferentiate and acquire stemness properties suggests an alternative and additional explanation for 
the origin of “cancer-initiating” cells and reopens the debate of the contribution of somatic cells to cancer progression.
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Adult stem cells are normally located in a niche where they remain quiescent until triggered to regener-
ate a wounded tissue. In physiological conditions, complex protein networks regulate their homing and 
their proliferation, protect them from apoptosis during migration and control their differentiation in 
harmony with the wounded tissue. According to the stem cell theory, signals mimicking tissue damages, 
promoting stem cell recruitment or favoring their proliferation and migration are susceptible to favor 
tumor progression. Most of the proteins that regulate stem cell migration in the embryo have now been 
deﬁ  ned as essential for adult stem cell proliferation and survival. Their expression in cancers can 
therefore been interpreted as a consequence of the stem/progenitor cell origin of cancers. Nevertheless, 
an increasing number of genes, that fulﬁ  ll diverse embryonic functions, also turn out to be reactivated 
in cancers. Interestingly, the deregulation of several of these genes, including Twist, Shp2, K-Ras and 
NF-1, is also associated with developmental diseases such as Saerthre-Chotzen, Noonan and LEOPARD 
syndromes, strengthening the general idea that cancer could be a developmental disease
1,2. Whether the 
detection of embryonic proteins is a consequence of the progenitor cell origin of cancers or rather por-
trays cancers as an embryonic disease is still a matter of discussion. Elucidating this point will require 
to determine whether embryonic genes are expressed in the original targeted cell or induced at speciﬁ  c 
and more advanced stages of tumor progression.
To debate this question, we proposed to focus on regulators of the epithelio-mesenchymal transition 
(EMT). EMT has emerged as a central process during embryonic development. It is involved in the 
morphogenics processes underlying parietal endoderm formation and gastrulation, as well as during 
the formation of several organs and tissues, such as the neural crest (NC), the heart, the musculoskeletal 
system, the craniofacial structures and the peripheral nervous system. Various signaling pathways, 
including the EGF, HGF, Met, Wnt-β-catenin, TGFβ, Notch and Hedgehog pathways are known to 
regulate EMT.
3,4 They all converge to a restricted number of transcription factors including the Id and 
Twist proteins, the homeobox SIP1 as well as the zinc ﬁ  nger proteins Snai1 and Snai2.
5,6 Whereas Id 
proteins inhibit EMT
7, Snai1, Snai2, SIP1 and Twist conversely promote the transition.
8,9 All four EMT 
inducers are essential for mesoderm patterning during embryonic development and are associated with 
the metastatic potential of cancer cells.
10–12 In vivo detection of Snai1 at the invasive front of colorectal 
cancers, in association with p16
INK4A expression, emphasizes the role of the protein in EMT and metastatic 
potential determination, by promoting growth-arrest and thereby cell synchronization as required for 364
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EMT induction.
13,14 How and at what stage of 
tumor progression are these genes induced? We 
recently showed that Twist expression overrides 
oncogene-induced senescence and apoptosis sug-
gesting that it might promote benign to malignant 
conversion.
15 Although to be shown, through their 
anti-apoptotic properties, Snai1 and Snai2 might 
also be linked to failsafe program escape. In con-
tradiction with a possible role in the earliest steps 
of tumor progression, Twist and Snai1 expression 
is induced by hypoxia and known to promote 
angiogenesis.
16–18 From these observations, one 
could assume that the reactivation of embryonic 
genes in premalignant tissues helps cells to over-
ride oncogene-induced failsafe programs whereas 
in hypoxic conditions it favors neo-angiogenesis 
or cell dissemination to less hostile environments, 
two possibilities that might not be mutually exclu-
sive. Indeed, the protein expression levels required 
for each of the functions might differ. There is 
little data on Twist, Snai1 and Snai2 expression at 
the earliest steps of tumor progression. Twist has 
been described as undetectable in premalignant 
tissues although a weak or a restricted expression 
to a limited number of cells remain difﬁ  cult to 
exclude.
19–21
Although still partial, convergent information 
tends to indicate that these proteins might also play 
a role in adult stem cells or progenitors cells. EMT 
has been associated with the earliest step of stem 
cell differentiation. Accordingly, Snai1 and Snai2 
have been shown to contribute to NC delamination 
and migration in chicks and Xenopus, although 
these functions might not be conserved in 
rodents.
22–25 Additionally, phenotypic examination 
of Snai2 deﬁ  cient mice highlights the role of the 
protein in the migration of three stem cell popula-
tions, melanoblasts, hematopoietic progenitors and 
germ cells resulting in pigmentation anomalies, 
gonadal defect and macrocytic anemia.
26 Snai2 
was also found expressed in neurogenin3-positive 
endocrine progenitor cells, partially differentiated 
cells derived from the undifferentiated multipotent 
epithelial cells of the pancreatic duct-like epithe-
lium.
27 Snai1 was recently described as implied in 
bone mesenchymal stem cell migration.
28 Although 
Snai1, Snai2 and Twist were found being expressed 
in neural crest-derived corneal precursors,
29 poor 
information regarding the status of Twist in pro-
genitor cells is yet available. Altogether, these 
observations raise the possibility that these tran-
scription factors assume essential functions in 
stem/progenitor cells by regulating their survival 
during migration. If we consider that these cells 
are at the origin of cancers, their detection in 
tumors is logically expected. Accidental oncogene 
activation promotes stem/progenitor cell growth. 
Twist, and potentially Snai1 and Snai2, override 
oncogene-induced failsafe programs, extend cell 
growth capabilities and cooperate with oncogenes 
to promote an EMT, as observed in epithelial cells. 
Depending on the differentiation status of the pro-
genitor cell affected and the pattern of proteins 
expressed, the resulting cancer type might vary. As 
an example, Pax proteins protect precursor cells 
from apoptosis during their migration through the 
embryo. Normally undetectable in adult tissues, 
Pax genes are overexpressed in various cancers, in 
link with their embryonic role.
30,31 For instance, 
Pax3, which is important for NC- differentiation 
into melanocyte during development,
32 is overex-
pressed in melanoma.
30,33,34 Pax2 and Pax8, which 
play an important role in early urogenital 
development, are essential for tumor progression 
and survival in several cancers of urogenital 
origins.
31
Although there is increasing evidence in support 
of the stem cell theory, does it deﬁ  nitively exclude 
that initial events might also hint differentiated 
cells? Various observations clearly indicate that 
cell differentiation is not an irreversible cellular 
state. Experimental grafting of human basal cell-
depleted epidermal sheets to immunodeﬁ  cient mice 
has clearly demonstrated that the dedifferentiation 
of differentiated epidermal cells into stems cells 
or stem cell-like cells is part of in vivo tissue regen-
eration.
35 Similarly renal proximal tubular cell 
(RPTC) dedifferentiation is thought to be a prereq-
uisite for regenerative proliferation and migration 
after renal injury.
36,37 Whether this process opens 
a window sufﬁ  cient to accumulate the number of 
mutations required to fully transform the cells is 
difﬁ  cult to estimate. However, primary mutations 
or epigenetic alterations might generate a genetic 
instability, thus favoring the accumulation of fur-
ther events. Indeed, recent studies have shown that 
abnormal epigenetic changes occur at various 
stages of tumor progression, mainly during the 
earliest steps of the neoplastic process. For exam-
ple, the Wnt pathway is known to be abnormally 
activated in colon cancers through epigenetic 
changes;
38 it is reasonable to assume that additional 
EMT inducers and embryonic pathways are simi-
larly turned on. Whether reactivation of embryonic 365
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genes contributes to enhance, or takes direct part 
in this dedifferentiation program also remains to 
be determined. Anyway, these observations clearly 
open an alternative to the stem cell theory for the 
generation of pluripotent cancer cells. Of note, the 
recently established link between EMT and 
stemness acquisition supports such a possibility.
39 
Further investigations are required to fully validate 
one or both of these cancer-origin theories. In 
particular, the development of animal models in 
which stem cells would be marked and followed 
independently of their differentiation status to 
unravel their contribution to carcinogen- or 
mutagen-induced tumors would be of particular 
help. Elucidating the contribution of embryonic 
genes to the earliest phases of tumor progression 
will also be crucial for clarifying the debate around 
the origin of cancers.
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